Video

Panobinostat in Relapsed/Refractory Multiple Myeloma

Related Videos
Douglas W. Sborov, MD, MS
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
Michel Delforge, MD, PhD
Ashraf Z. Badros, MBCHB, professor, medicine, Medical Oncology, Hematology Oncology, University of Maryland Medical System
Binod Dhakal, MD
Michel Delforge, MD, PhD, professor, Faculty of Medicine, Department of Hematology, director, member, Leuven Cancer Institute, member, Senior Academic Staff, Council of the Faculty of Medicine, Council of the Department of Oncology, University Hospital Leuven, University of Leuven
Ajay K. Nooka, MD, MPH, FACP
Meletios A. Dimopoulos, MD
Binod Dhakal, MD
In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil, discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
Related Content
The OncFive: Top Oncology Articles for the Week of 11/10
November 16th 2024

The OncFive: Top Oncology Articles for the Week of 11/10

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

LASZLO – stock.adobe.com
November 14th 2024

Belantamab Mafodotin Plus Bortezomib/Dexamethasone Extends OS in R/R Myeloma

Paul G. Richardson, MD
October 2nd 2023

Richardson Reviews Findings and Future Directions With Mezigdomide Plus Dexamethasone in R/R Myeloma

FDA
November 6th 2024

FDA Grants Orphan Drug Designation to LBL-034 for Multiple Myeloma

Shaji Kumar, MD, research chair, Division of Hematology, consultant, Division of Hematology, professor, medicine, Mayo Clinic
November 6th 2024

Notable 2024/Early 2025 Multiple Myeloma NCCN Guideline Updates Feature Quadruplets and More